INO 4212

Drug Profile

INO 4212

Alternative Names: GLS 5200; INO 4212 SynChon® Ebola immunotherapy; INO 4212 SynCon® vaccine; INO4212; VGX 4212

Latest Information Update: 18 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Inovio Pharmaceuticals
  • Class DNA vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Ebola virus infections

Most Recent Events

  • 11 Apr 2017 Efficacy data from a phase I trial in Ebola virus infections released by Inovio
  • 11 Apr 2017 Pharmacodynamics data from a preclinical study in Ebola virus infections released by Inovio
  • 15 Mar 2017 Inovio Pharmaceuticals completes enrolment in an expansion study of the phase I trial for Ebola virus infection (In volunteers) in USA (NCT02464670; 9213076)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top